

## CURRICULUM VITAE

**NAME** David A. Katzenstein, MD

**BUSINESS ADDRESS** Division of Infectious Disease  
S-156 Stanford Univ. Medical Center  
Stanford, California 94305

**ADDRESS** 3540 La Honda Rd. / PO Box 73  
San Gregorio, California 94074

**E- MAIL** Davidkk@stanford.edu

**TELEPHONE** 650-725-8304 (work)  
650-725-2395 (FAX)  
650-747-0018 (home)  
650-868-7250 (cell)

**BIRTH DATE** January 3, 1952  
Hartford, Connecticut

### EDUCATION

1968 - 1973 B.A. (Biology), University of California San Diego

1973 - 1977 M.D., University of California San Diego, School of Medicine

1977 - 1978 Internship, Internal Medicine, University of New Mexico

1978 - 1980 Residency, Internal Medicine, University of California San Diego

1980 - 1981 Fellowship, Infectious Diseases, University of California San Diego

1981 - 1983 Fellowship, Infectious Diseases, University of California Davis

### EMPLOYMENT

1982 - 1984 Assistant Clinical Professor of Medicine, Division of Infectious Diseases  
University of California Davis, Martinez Veterans Administration Hospital

1984 - 1986 Assistant Professor of Medicine, Division of Infectious Diseases  
University of Minnesota

1986 - 1987 Lecturer, Department of Medical Microbiology  
Godfrey Huggins School of Medicine, University of Zimbabwe

1987 - 1989 Senior Research Fellow, Laboratory of Retrovirus Research

Center for Biologics Evaluation and Research, Food and Drug Administration

- 1989 - 1991 Physician Specialist and Clinical Assistant Professor of Medicine  
Division of Infectious Diseases, Stanford University  
Associate Medical Director, Stanford University AIDS Clinical Trial Group
- 1991 - 1992 Acting Assistant Professor, Division of Infectious Diseases, Stanford University  
Associate Medical Director, Stanford University AIDS Clinical Trial Group  
Co-Director, Diagnostic Virology Laboratory, Stanford University Hospital
- 1992 - 1997 Assistant Professor, Division of Infectious Diseases, Stanford University  
Associate Medical Director, Stanford University AIDS Clinical Trial Group  
Co-Director, Diagnostic Virology Laboratory, Stanford University Hospital
- 1997 Associate Professor, Division of Infectious Diseases, Stanford University  
Associate Medical Director, Stanford University AIDS Clinical Trial Group  
Co-Director, Diagnostic Virology Laboratory, Stanford University Hospital

### **BOARD CERTIFICATION**

- 1980 American Board of Internal Medicine  
1989 American Board of Internal Medicine Infectious Disease

### **LICENSURE**

- 1978 California G-37880  
1984 Minnesota 28946  
1986 Zimbabwe

### **PROFESSIONAL and SCIENTIFIC SOCIETIES**

American Society for Microbiology  
Infectious Disease Society of America  
Society for General Microbiology  
International AIDS Society  
American Federation for Clinical Research

### **GRANTS AND AWARDS**

- 1982 Principal Investigator. Pathogenesis of Acute and Latent MCMV in Splenic Macrophages. June 1982 - May 1984. Veterans Administration Career Development Award.
- 1983 Co-investigator. Epidemiology of Sexually Transmitted Viral Infections. Jan 1983 - December 1984. Veterans Administration Research Project.
- 1984 Principal Investigator. Molecular Pathogenesis of Varicella Zoster Virus. October 1984 - October 1985. Minnesota Medical Foundation.

- 1985 Principal Investigator. A Murine Model of Graft Versus Host Disease and CMV Infection. January 1985 - December 1985. Minnesota Medical Foundation
- 1985 Principal Investigator. Retrovirus Cultures in AIDS. March 1985 - February 1986. Minnesota Hospital Foundation.
- 1986 Principal Investigator. Characterization of T-lymphotropic Retrovirus Infection in Zimbabwe. July 1986 - June 1987. University of Zimbabwe Research Council.
- 1992 Principal Investigator. Preparation for AIDS/HIV Vaccine Evaluation in Zimbabwe.  
Sponsor: Division of AIDS, NIAID, R21 AI33868.  
Project: 9-30-92 -- 8-31-95
- 1992 Principal Investigator. Investigation of VaxSyn versus ZDV in asymptomatic HIV infected individuals. Sponsor: Wyeth-Ayrst Pharmaceuticals.  
Project: 6-01-92 -- 5-31-94
- 1992 Project Director. Virology Core and Developmental, AIDS Clinical Trials Unit.  
Sponsor: NIAID, U19 AI27666. (Thomas C. Merigan - principle investigator)  
Project: 3-1-92--12-31-95
- 1994 Principal Investigator. Zimbabwe AIDS Prevention Project / Peer Intervention HIV transmission. Sponsor: Family Health International, NIAID, NOL AI35173-129.  
Project: 9-01-94--9-29-98
- 1995 Principal Investigator. Perinatal Transmission of HIV Infection in Zimbabwe.  
Sponsor: NIAID, NICHD, DAIDS, R01 AI39013.  
Project: 9-30-95--8-31-2000
- 1996 Principal Investigator. Virology Advanced Technology Laboratories, Adult AIDS Trials Group. Sponsor: NIAID, U19 AI27666.  
Project: 1-1-96 --12-31-99
- 1999 Principal Investigator, Silver Ion Therapeutics in HIV, Sponsored by Arrow International.
- 2000 - Doris Duke Distinguished Clinical Scientist Award. Affordable Feasible Treatment for HIV infected Women in Southern Africa. Doris Duke Charitable Trust.

## JOURNAL ARTICLES

1. McCutchan JA, Katzenstein DA, Norquist D, Chikami G, Wunderlich A, Braude AI. Role of Blocking Antibody in Disseminated Gonococcal Infection. Journal of Immunology, 121:1184, 1978.
2. Kaplan JE, Davis LE, Narayan V, Koster J, Katzenstein DA. Botulism, Type A and Treatment with Guanidine, Annals of Neurology, 6: 69, 1979.
3. Katzenstein DA, Rickerson V, and Braude AI. New Concepts of Amoebic Liver Abscess. Medicine, 61: 237-46, 1982.
4. Katzenstein DA, Yu G, and Jordan MC. Lethal Murine Cytomegalovirus (MCMV) Infection is Mediated by Early Replication in Splenic Macrophages. Journal of Infectious Diseases, 148: 406-411, 1983.
5. Katzenstein DA, Ciafalo L, Mays C. Bordatella Bronchiseptica Bacteremia. Western Journal of Medicine, 140: 98, 1984.
6. Martin D, Katzenstein DA, Yu G, and Jordan MC. CMV Viremia Detected by Nucleic Acid Hybridization and Electron Microscopy. Annals of Internal Medicine, 100: 222-225, 1984.
7. Katzenstein DA. Isolated Candida Arthritis. Report of a case and definition of a clinical syndrome. Arthritis and Rheumatology, 28: 1431-26, 1985.
8. Katzenstein DA, Crane RT and Jordan MC. Successful treatment of murine cytomegalovirus disease does not prevent latent infection. Journal of Laboratory and Clinical Medicine, 90: 155-60. 1986.
9. Brummet CF, Cherrington JM, Katzenstein DA, Juni BA, Van Drunen NV, Edelman C, Rhame FS, and Jordan, MC. Nosocomial adenovirus infection: molecular epidemiology of an outbreak due to adenovirus 3a. Journal of Infectious Diseases, 158: 423-432, 1988.
10. Mason PR, Katzenstein DA, Chimbira T, Mtimavalye L. Microbial flora of the lower genital tract of women in labor at Harare Maternity Hospital. Central African Journal of Medicine, 35: 337-343, 1989.
11. Mason PR, Katzenstein DA, Chimbira T, Mtimavalye L. Vaginal flora of women admitted to hospital with signs of sepsis following normal vaginal delivery, caesarian section, or abortion. Central African Journal of Medicine, 35: 344-51, 1989.
12. Mason PR, Gwanzura L, Chimbira T, Mtimavalye L, Nathoo J, and Katzenstein DA. Antimicrobial susceptibility of Neisseria gonorrhoeae isolated from maternal and child infections in Harare. Central African Journal of Medicine, 35: 367-71, 1989.
13. Latif AS, Katzenstein DA, Bassett MT, Houston S, Emmanuel JC, and Marowa E. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS, 3: 519-23,

1989.

14. Katzenstein DA, Latif AS, Grace S, Basset MT, Mashu A, deVilliers DM, Carrow EW, Hendry RM, Marowa E, and Emmanuel JC. Clinical and Laboratory Characteristics of Human Immunodeficiency Virus Infection in Zimbabwe. Journal of Acquired Immune Deficiency Syndromes, 3: 701-707, 1990.
15. Sawyer LA, Katzenstein DA, Hendry RM, Boone J, Vujcic LK, Williams CC, Zeger S, Saah AJ, Rinaldo CR, Phair JP, Giorgi JV, and Quinnan GV. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in HIV infection. AIDS and Human Retrovirus Research, 6: 341-355, 1990.
16. Vujcic L, Katzenstein DA, Martin M, Quinnan G, and Collaborating laboratories. International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus. AIDS and Human Retrovirus Research, 6: 847-853, 1990.
17. Katzenstein DA, Vujcic L, Latif AS, Boulos R, Halsey N, Quinn TC, Rastogi SC, and Quinnan GV. Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans. Journal of Acquired Immune Deficiency Syndromes, 3: 810-816 1990.
18. McLeod DT, Neill P, Robertson VJ, Latif AS, Emmanuel JC, Els JE, Gwanzura LKZ, Trijssenaar FEJ, Nziramasanga P, Jongeling GR, Katzenstein DA, Nkanza N, and Lucas SB. Pulmonary diseases in patients infected with the human immunodeficiency virus in Zimbabwe, Central Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 83: 694-697, 1991.
19. Holodniy MD, Kim S, Katzenstein DA, Konrad M, Groves E, and Merigan TC. Inhibition of Human Immunodeficiency Virus Gene Amplification by Heparin. Journal of Clinical Microbiology, 89: 676-679, 1991.
20. Merigan, TC and Katzenstein, DA. Pathogenesis of Human Immunodeficiency Virus Infection Related to Various Strategies in Its Control. Reviews in Infectious Disease, 13: 292-302, 1991.
21. Holodniy M, Katzenstein DA, Sengupata S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, and Merigan TC. Detection and Quantification of HIV-1 RNA in Patient Serum Using the Polymerase Chain Reaction. Journal of Infectious Diseases 163: 862-866, 1991.
22. Mermin JH, Holodniy M, Katzenstein DA, and Merigan TC. Detection of HIV DNA and RNA in Semen by the Polymerase Chain Reaction. Journal of Infectious Diseases, 164: 769-772, 1991.
23. Holodniy M, Katzenstein DA, Israelski DM, and Merigan TC. Reduction in Plasma Human Immunodeficiency Virus Ribonucleic Acid Following Dideoxynucleoside Therapy as Determined by the Polymerase Chain Reaction. Journal of Clinical Investigation, 88: 1755-1759, 1991.

24. Clark AGB, Holodniy M, Schwartz DH, Katzenstein DA, and Merigan, TC. Decrease in HIV Provirus in Peripheral Blood Mononuclear Cells During Zidovudine and Human rIL-2 Administration. Journal of Acquired Immune Deficiency Syndromes, 5: 52-59, 1992.
25. Katzenstein DA, Holodniy M, Israelski DM, Sengupta S, Mole LA, Bubp JL, and Merigan, TC. Plasma Viremia in Human Immunodeficiency Virus Infection: Relationship to Stage of Disease and Anti-viral Treatment. Journal of Acquired Immune Deficiency Syndromes, 5: 107-112, 1992.
26. Merigan TC, Clark G, Katzenstein DA, and Holodniy M. Correlation Between Human Immunodeficiency Virus (HIV) Load, Stage of Disease and Diodeoxy Drug Administration Using Quantitative RNA and DNA Polymerase Chain Reaction (PCR) and Viremia Measurements. In Viral Quantitation in HIV Infection, (Edited by J-M Andrieu, John Libbey Eurotext, Paris). 147-152, 1992.
27. Winters MA, Holodniy M, Katzenstein DA, and Merigan TC. Quantitative RNA and DNA Gene Amplification Can Rapidly Monitor HIV Infection and Antiviral Activity in Cell Cultures. PCR Methods and Applications, 1: 257-62, 1992.
28. Blumenfeld W, McCook O, Holodniy M, Katzenstein DA. Correlation of microbiologic and cytologic demonstration of *Pneumocystis carinii* with the presence of amplified DNA. Modern Pathology, 5: 103-106, 1992.
29. Mohle-Boetani J, Akula SK, Holodniy M, Katzenstein DA, Garcia G. The sulfone syndrome in a patient receiving dapsone prophylaxis for *Pneumocystis carinii* pneumonia: a case report and review of the literature. Western Journal of Medicine, 156: 303-6, 1992.
30. Kundu S, Katzenstein D, Moses LE, Merigan TC. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activity in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proceeding National Academy Sciences, USA, 89: 11204-8, 1992.
31. Bassett MT, Latif AS, Katzenstein DA, Emmanuel JC. Sexual behavior and risk factors for HIV infection in a group of male factory workers who donated blood in Harare, Zimbabwe: Journal of Acquired Immune Deficiency Syndromes, 5: 556-9, 1992.
32. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, and Merigan TC. A Mutation in HIV Reverse Transcriptase and Decline in CD4 Lymphocyte Numbers in Long Term Zidovudine Recipients. Journal of Infectious Diseases, 167: 526-532, 1993.
33. Shafer RW, Kozal MJ, Katzenstein DA, Lipil WH, Johnstone IF, and Merigan TC. Zidovudine Susceptibility Testing of Human Immunodeficiency Virus Type 1 (HIV) Clinical Isolates. Journal of Virologic Methods, 41: 297-310, 1993.
34. Wood R, Dong H, Katzenstein DA, and Merigan TC. Quantification and Comparison of HIV-1 Proviral Load in Peripheral Blood Mononuclear Cells and Isolated CD4+ T Lymphocytes. Journal of Acquired Immune Deficiency Syndromes, 6: 237-240, 1993.

35. Holodniy M, Katzenstein DA, Winters M, Montoya J, Shafer R, Kozal M, Ragni M, and Merigan TC. Measurement of HIV Virus Load and Genotypic Resistance by Gene Amplification in Asymptomatic Subjects Treated with Combination Therapy. Journal of Acquired Immune Deficiency Syndromes, 6: 366-369, 1993.
36. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, and Merigan TC. Detection of Human Immunodeficiency Virus Type 1 in Semen: Effects of Disease Stage and Nucleoside Therapy. Journal of Infectious Diseases, 167: 798-802, 1993.
37. Montoya J, Wood R, Katzenstein DA, Holodniy M, and Merigan, TC. Peripheral Blood Mononuclear Cell DNA Quantification for Diagnosis of Human Immunodeficiency Virus Infection in Adults. Journal of Clinical Microbiology, 31 :2692-6, 1993.
38. Winters MA, Tan LB, Katzenstein DA, and Merigan TC. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. Journal of Clinical Microbiology, 31: 2960-6, 1993.
39. Katzenstein DA, Winters M, Israelski D, Bupp J, Winger E, and Merigan TC. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long term therapy with Zidovudine. Journal of Infectious Diseases, 169: 416-9, 1994.
40. Shafer RW, Kozal MJ, Winters MA, Iversen AKN, Katzenstein DA, Ragni MV, Meyer WA III, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S, and Merigan TC. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique pol gene mutations. Journal of Infectious Diseases, 169: 722-9, 1994.
41. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, and Merigan TC. Failure of short term CD4-PE40 infusions to reduce viral load in human immunodeficiency virus infected individuals. Journal of Infectious Diseases, 170: 1009-13, 1994.
42. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, and Merigan TC. Didanosine resistance mutation in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals of Internal Medicine, 121: 263-268, 1994.
43. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguniga E, Halpern J, and Merigan TC. HIV-1 syncytium inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in Zidovudine treated patients. Journal of Acquired Immune Deficiency Syndromes, 7: 832-38, 1994.
44. Ramachandran RV, Katzenstein DA, and Merigan TC. Long-term effects of interleukin-2 on CD4 cell counts in human immunodeficiency virus-infected patients. (letter) Journal of Infectious Diseases, 170: 1044-6, 1994.
45. Mbizvo MT, Ray S, Bassett M, McFarland W, Machekano R, and Katzenstein DA. Condom use and the risk of HIV infection: who is being protected? Central African

Journal of Medicine, 40: 294-9, 1994.

46. McFarland W, Kahn JG, Katzenstein DA, Mvere D, and Shamu R. Deferral of blood donors with risk factors for HIV infection saves lives and money in Zimbabwe. Journal of Acquired Immunodeficiency Syndromes, 9: 183-192, 1995.
47. Fiscus S, DeGruttola V, Gupta P, Katzenstein DA, Meyer WA III, Lafaro ML, Katzman M, Ragni MV, Reichelderfer PS, and Coombs RW. Human Immunodeficiency Virus type-1 quantitative cell microculture as a measure of antiviral efficacy in a multi-center clinical trial. Journal of Infectious Diseases, 171: 305-11, 1995.
48. Collier AC, Coombs RW, Katzenstein DA, Holodniy M, Gibson J, Mordenti J, Izu AE, Duliege AM, Ammann AJ, Merigan TC, and Corey L. Safety, pharmacokinetics and antiviral response of CD4-Immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10: 150-6, 1995.
49. Shafer RW, Iversen AKN, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC, and the AIDS Clinical Trials Group 143 Virology Team. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. Journal of Infectious Diseases, 172: 70-8, 1995.
50. Katzenstein DA. Virol Phenotype and Genotype as Markers in Clinical Trials. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 10 (Supplement 2) S25-S34, 1995.
51. Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, and Merigan TC. Polyethylene Glycol-Modified Interleukin-2 and Thymosin Alpha 1 in Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 173: 1005-08, 1996.
52. Valentine FT, Kundu S, Haslett PAJ, Katzenstein D, Beckett L, Spino C, Borucki M, Vasquez M, Smith G, Korvick J, Kagan J, and Merigan TC. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus-infected individuals with > 400 CD4 T lymphocytes/mm<sup>3</sup> [ACTG 137]. Journal of Infectious Diseases, 173: 1336-46, 1996.
53. Carpenter CCJ, Fischl M, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner J, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, and Volberding PA. Antiretroviral Therapy for HIV Infection in 1996: Recommendations of an International Panel. Journal of the American Medical Association, 276(2): 146-54, 1996
54. Holodniy M, Katzenstein DA, Mole L, Winters M, and Merigan TC. Human Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing

- Phenotype. Journal of Infectious Diseases, 174: 854-57, 1996.
55. Goulston C, Stevens E, Gallo D, Mullins J, Hansen C, and Katzenstein DA. Human Immunodeficiency Virus in Plasma and Genital Secretions during the menstrual cycle. Journal of Infectious Diseases, 174: 858-61, 1996.
  56. Hammer SM, Katzenstein DA, Hughes M, Gundacker H, Blaschke T, Schooley RT, Simpson D, Haubrich R, Henry WK, Lederman M, Phair JP, McLaren C, Rooney J, Salgo M, Nui M, Hirsch MS, and Merigan TC. Nucleoside monotherapy vs. Combination therapy in HIV infected adults: A randomized, double blind, placebo controlled trial in persons with CD4 cell counts between 200 and 500 per cubic millimeter. New England Journal of Medicine, 335(15) : 1081-90, 1996.
  57. Katzenstein DA, Hammer SM, Hughes M, Gundacker H, Jackson B, Fiscus S, Lathey J, Rasheed S, Elbeik T, Reichman R, Japour A, Scott W, Griffiths B, Winters M, Merigan TC, and Hirsch M. Virologic and Immunologic Markers and Clinical Outcomes After Nucleoside Therapy in Adults With 200 to 500 CD<sub>4</sub> Cells Per Cubic Millimeter. NIAID Sponsored AIDS Clinical Trials Group Study 175, A Virology Substudy. New England Journal of Medicine, 335: 1091-98, 1996.
  58. Basset M, Ray S, Mbizvo M, Machezano R, van de Wijgert J, McFarland W, Katzenstein DA. Risk factors for HIV infection at enrollment in an urban male factory cohort in Harare, Zimbabwe. Journal of Acquired Immune Deficiency Syndromes and Retrovirology, 13: 287-93, 1996.
  59. Mbizvo M, Ray S, Machezano R, Latif W, McFarland W, Katzenstein DA. HIV seroincidence and behavioral correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe. AIDS; 10: 895-901, 1996.
  60. Mason PR, Gwanzura L, Latif A, Ray S, van de Wijgert J, Katzenstein DA. Antimicrobial susceptibility patterns amongst group B streptococci from women in Harare, Zimbabwe. International Journal of Antimicrobial Agents ( in press, 1996).
  61. Ray S, Mason PR, Smith H, Rogers L, Tobaiwa O, Katzenstein DA. An evaluation of dipstick ELISA in the detection of antibodies to HIV-1 and 2 in Zimbabwe. Tropical Medicine and International Health, 2(1): 83-88, 1997.
  62. Yen-Lieberman B, Brambila D, Jackson B, Bremer J, Coombs R, Cronin M, Katzenstein D, Leung S, Lin P, Palumbo P, Rasheed S, Todd J, Vahey M, Reichelderfer P. Preliminary evaluation of a quality assurance program (QAP) for detection of Human Immunodeficiency Virus type 1 plasma RNA by the AIDS Clinical Trials Group. Journal of Clinical Microbiology 43: 2695-270, 1996;
  63. David Katzenstein. Antiretroviral Therapy for Human Immunodeficiency Virus Infection in 1997. Western Journal of Medicine, 166: 319-325, 1997.
  64. Carpenter CCJ, Fischl M, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner J, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, and Volberding PA. Antiretroviral Therapy for HIV Infection in 1997: Updated Recommendations of an International AIDS Society - USA Panel. Journal of the American Medical Association, 277: 1962-69, 1997.

65. Mbizvo MT, Latif AS, Machezano R, MaFarland R, Bassett MT, Ray S, Katzenstein D. HIV seroconversion among factory workers in Harare: who is getting newly infected ? Central African Journal of Medicine, 43: 135-9, 1997.
66. Shafer RW, Eisen J, Merigan TC, Katzenstein DA. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Journal of Virology, 71: 5441-5448, 1997.
67. McFarland W, Mvere D, Katzenstein D. Risk factors for prevalent and incident HIV infection among volunteer blood donors in Harare, Zimbabwe: implications for blood safety. AIDS, 11: S97-S102.
68. Kundu SK, Katzenstein D, Valentine FT, Spino C, Efron B, Merigan TC. Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and Plasma RNA: Relationship to cellular immune responses. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 15: 269-74, 1997.
69. Raboud JM, Montaner JSG, Rae S, Kahn J, Hammer SM, Katzenstein DA. Meta-analysis of five randomized controlled trails comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. Antiviral Therapy, 2(4): 237-247, 1997.
70. McFarland W, Mvere D, Shamu R, Katzenstein D. Risk factors for HIV infection among first-time blood donors in Zimbabwe. Transfusion 38:279-284, 1998.
71. Lenderking WR, Testa MA, Katzenstein D, Hammer S. Measuring quality of life in early HIV disease: the modular approach. Quality of Life Res, 6: 515-30, 1997.
71. Montano MA, Novitky VA, Blackard JT, Cho NL, Katzenstein DA, Essex M. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. Journal of Virology, 71: 8657-8665, 1997.
72. Mason PR, Gwanzura L, Latif A, Marowa E, Ray S, Katzenstein DA. Antimicrobial resistance in gonococci isolated from patients and from commercial sex workers in Harare, Zimbabwe. International Journal of Antimicrobial Agents 1997; 9:175-179.
73. Delwart EL, Mullins JI, Gupta P, Learn G, Holodniy M, Katzenstein D, Waler B, Singh MK. Human immunodeficiency virus type 1 populations in blood and semen. Journal of Virology, 72: 617-623, 1998.
74. Goulston C, McFarland W, Katzenstein DA. Human Immunodeficiency Virus Type 1 RNA Shedding in the Female Genital Tract. Journal of Infectious Diseases, 177: 1100-1103, 1998.
75. Roesel DJ, Gwanzura L, Mason PR, Joffe M, Katzenstein, DA. Polymerase chain reaction of *Haemophilus ducreyi* DNA. Sex Transm Inf., 74:63-65, 1998.
76. Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson B, Rasheed S, Elbeik T, Reichman R,

- Japour A, D'Aquila RT, Scott W, Griffiths BP, Hammer SM, Katzenstein DA. Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1- infected patients with 200-500 CD4 cells/ mm<sup>3</sup> (ACTG 175). Journal of Infectious Diseases, 177:617-624, 1998.
77. Fiscus SA, Hughes MD, Lathey JL, Pi T, Jackson B, Rasheed S, Elbeik T, Reichman R, Japour A, Byington R, Scott W, Griffiths BP, Katzenstein DA, Hammer SM. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in HIV-1 infected adults treated with nucleosides. Journal of Infectious Diseases, 177: 625-33, 1998.
  78. Marschner I, Collier AC, Coombs RW, DAquila RT, DeGruttola V, Fischl M, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. Journal of Infectious Diseases, 177: 40-7, 1998.
  79. Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA. Human immunodeficiency virus type 1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to Zidovudine. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 17: 203-208, 1998.
  80. Gwanzura L, McFarland W, Alexander, Burke RL, Katzenstein, DA. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. Journal of Infectious Diseases, 17: 481-4, 1998.
  81. Zipeto D, Hong C, Gerna G, Zavattoni M, Katzenstein D, Merigan TC, Rasmussen L. Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. AIDS Res and Human Retro 14:533-6. 1998.
  82. Lynn Zijenah, Michael T. Mbizvo, Jonathan Kasule, Kusum Nathoo, Marshall Munjoma, Kassom Mahomed, Yvonne Maldonado, Simon Madzime, and David Katzenstein: Mortality in the first two years among infants born to HIV-infected women in Harare, Zimbabwe. Journal of Infectious Disease 1998; 178:109-113.
  83. Simpson D, Katzenstein D, Hughes MD, Hammer S, Williamson DL, Jiang Q, Pi Ju-Tsung and the ACTG 175/801 Study Team. Neuromuscular function in HIV infection: Analysis of a placebo-controlled antiretroviral trial. AIDS 1998 12:2425-2432.
  84. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society – USA Panel. Journal of the American Medical Association 280:78-86. 1998
  85. Ray S, Latif A, Machekano R, Katzenstein DA. Sexual behavior and risk assessment among urban male factory workers in Zimbabwe. Soc Sci Med 1998; 47:1431-43.
  86. Kastrissios H, Suárez J-R, Katzenstein D, Girard P, Sheiner LB, Blaschke TF: Characterizing patterns of drug-taking behavior with a multiple drug regimens in an AIDS clinical trial. AIDS 12:2295-2303, 1998.

87. Kastrissios H, Suárez JR, Hammer S, Katzenstein D, Blaschke TF: The extent of noncompliance in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. *AIDS* 12:2305-2311, 1998.
88. Machekano R, McFarland W, Mbizvo MT, Bassett MT, Katzenstein D, Latif AS. Impact of HIV Counselling and testing on HIV seroconversion and reported STD incidence among male factory workers in Harare, Zimbabwe. *Central Af J of Med* 44:98-102, 1998.
89. Gregson S, Machekano R, Donnelly CA, Mbizvo MT, Anderson RM, Katzenstein DA. Estimating HIV incidence from age-specific prevalence data: comparison of concurrent cohort estimates in a study of male factory workers, Harare, Zimbabwe. *AIDS* 12:2049-58, 1998.
90. Watts H, Spino C, Zaborski L, Katzenstein D, Hammer S, Benson C. A comparison of gynecologic findings in HIV positive women with CD4 lymphocyte counts between 200 and 500 / ml and below 100 / ml *JAIDS* 1999; 20:455-462.
91. Juno Min and David Katzenstein. Detection of Kaposi's Sarcoma-Associated Herpes virus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's Sarcoma, CD4 cell count and HIV RNA levels. *AIDS Res Hum Retro* 1999;15:51-55.
92. Shafer RW, Chaung T, Hsu P, White CB, Katzenstein DA. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe *AIDS Res Hum Retro* 1999;15:65-69.
93. Tien PC, Chiu T, Latif A, Ray S, Batra M, Contag CH, Zejenah L, Mbizvo M, Delwart EL, Mullins JI, Katzenstein DA. Primary Subtype C HIV-1 Infection in Harare, Zimbabwe. *J Acquired Imm Def Syndr Hum Retro* 20:147-153 1999.
94. D A Katzenstein, M Mbizvo L Zijenah, T Gittens, M Munjoma, D Hill, S Madzime, Y Maldonado. Serum level of Maternal Human Immunodeficiency Virus (HIV) RNA, Infant Mortality and Vertical transmission of HIV in Zimbabwe. *J Infect Dis* 1999;179:1382-87.
95. Brambilla D, Reichelderfer PS, Bremer JW, Shapiro DE, Hershov RC, Katzenstein DA, Hammer SM, Jackson B, Collier A, Sperling RS, Fowler MG, Coombs RW. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. *AIDS* 1999;13:2269-2279.
96. DA Katzenstein, S Kundu, J Spritzler, BR Smoller, P Hazlett, F Valentine TC Merigan. Delayed-type Hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen. *Journal of Acquired Immune Deficiency Syndromes* 1999;22:341-347.
97. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein DA, Merigan TC, Efron B. HIV-1 genotypic resistance patterns predict responses to Saquinavir-Ritonavir therapy in patients in whom previous protease inhibitor therapy has failed. *Annals of Internal Medicine* 1999;131:813-821.

98. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society – USA Panel. Journal of the American Medical Association 2000;283:381-390.
99. HIV Trialists' Collaborative Group. Zidovudine, didanosine and zalcitabine in the treatment of HIV infection: meta-analysis of the randomised evidence. *Lancet* 1999;353:2014-25.
100. William McFarland, Lovemore Gwanzura, Mary T. Bassett, Rhoderick Machekano, Ahmed S. Latif, Catherine Ley, Julie Parsonnet, Rae Lyn Burke, and David Katzenstein. Prevalence and Incidence of Herpes Simplex Virus Type 2 Infection among Male Zimbabwean Factory Workers. *The Journal of Infectious Diseases* 1999;180:1459-1465.
101. Lovemore Gwanzura, Ahmed Latif, Mary Bassett, Rhoderick Machekano, David A Katzenstein, Peter R Mason. Syphilis serology and HIV infection in Harare, Zimbabwe. *Sexually Transmitted Infections, Sex Transm Infect.* 1999 Dec;75(6):426-30.
102. Kim SY, Hughes MD, Hammer SM, Jackson BJ, DeGruttola V, Katzenstein DA. Both serum HIV-1 RNA levels and CD4+ lymphocyte counts predict outcome in HIV-1 infected subjects with 200 to 500 CD4 cells per cubic millimeter. *AIDS Research and Human Retroviruses* 2000;16:645-653.
103. Machekano RN, Bassett MT, Zhou PS, Mbizvo MT, Latif AS, Katzenstein DA. Report of sexually transmitted diseases by HIV infected men during follow up: time to target the infected ? *Sex Transmit Infect.* 2000; 76:188-192.
104. Maneesh B, Tien P, Shafer RW, Contag CH, Katzenstein DA. HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. *AIDS Res Hum Retroviruses.* 2000 Jul 1;16(10):973-9.
105. Lampinen T, Kulasingam S, Min J, Borok M, Gwanzura L, Lamb J, Mahomed K, Woelk GB, Strand K, Bosch ML, Edelman D, Constantine N, Katzenstein DA, Williams M. Detection of Kaposi's Sarcoma-associated herpesvirus in oral and genital secretions of Zimbabwean women. *J Infect Dis* 2000;181:1785-90.
106. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, Navia BA, Schifitto G, Katzenstein D, Rask C, Zaborski L, Smith ME, Shriver S, Millar L, Clifford DB, Karalnik IJ. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. *AIDS Clinical Trials Group Team 291.Neurology.* 2000 Mar 14;54(5):1080-8.
107. Machekano R, McFarland W, Hudes E, Bassett MT, Mbizvo MT, Katzenstein D. Correlates of HIV test results seeking and utilization of partner counseling services in a cohort of male factory workers in Zimbabwe. *AIDS and Behavior* 2000;4:63-70.
108. Chlamydia trachomatis in symptomatic and asymptomatic men: detection in urine by enzyme immunoassay. *Cent Afr J Med.* 2000 Mar;46(3):62-5.
109. DeGruttola V, Dix L, D'Aquila, R, Holder D, Phillips A, Ait-Khaled M, Baxter J,

- Clevenberg P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pednault L, Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy:re-analysis of retrospective and prospective studies using a standardized data analysis plan. *Antiviral Therapy* 2000;5:41-48.
110. MA Albrecht, MD Hughes, SH Liou, DA Katzenstein, R Murphy, HH Balfour, MF Para, H Valdez, SM Hammer. Effect of Lamivudine in HIV infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. *AIDS Research and Human Retroviruses* 2000;14:1337-1344.
  111. Currier J, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, Hammer SM, Cotton DJ. Differences between women and men in adverse events and CD4+ responses to nucleoside analog therapy for HIV infection. *Journal of Acquired Immune Deficiency Syndrome*. 2000; 24:316-324.
  112. D.A. Katzenstein, M.D. Hughes, M. Albrecht, S.H. Liou, et al for the ACTG 302 study team. Virologic and CD4+ cell responses to new nucleoside regimens:switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. *AIDS Research and Human Retroviruses*, 2000; 16:1031-1037.
  113. Roy M, Gulick, X. Joan Hu, Susan A. Fiscus, Courtney V. Fletcher, Richard Haubrich, Hailong Cheng, Edward Acosta, Stephen Lagakos, Ronald Swanstrom, William Freimuth, Sally Snyder, Charlotte Mills, Margaret Fischl, Carla Pettinelli, and David Katzenstein for the ACTG 359 Protocol Team. Randomized Study Of Saquinavir With Ritonavir Or Nelfinavir Together With Delavirdine, Adefovir Or Both In Hiv-Infected Adults With Virologic Failure On Indinavir: Aids Clinical Trials Group (Actg) Study 359. *J Infect Dis*. 2000 Nov;182(5):1375-84.
  114. Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, Miller MD, Van Doren S, Shafer RW, Katzenstein DA. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. *J Acquir Immune Defic Syndr* 2000 Mar 1;23(3):221-6.
  115. Guevara H, Johnston E, Zijenah L, Tobaiwa O, Mason P, Contag C, Mahomed K, Hendry M, Katzenstein D. Prenatal transmission of subtype C HIV-1 in Zimbabwe: HIV-1 RNA and DNA in maternal and cord blood. *J Acquir Immune Defic Syndr*. 2000 Dec 15;25(5):390-7.
  116. [Simpson DM](#), [Katzenstein D](#), [Haidich B](#), [Millington D](#), [Yiannoutsos C](#), [Schifitto G](#), [McArthur J](#). Plasma carnitine in HIV-associated neuropathy. *AIDS*. 2001 Nov 9;15(16):2207-8.
  117. DA Katzenstein, Hughes MD, Albrecht M, Liou SH, Murphy R, Balfour H, Para M, Hammer S. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection. *AIDS Res Hum Retroviruses*. 2001 Feb 10;17(3):203-10.

118. Shulman NS, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein DA, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J. Phenotypic hyper-susceptibility of non-nucleoside reverse transcriptase inhibitors in treatment experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. *AIDS*. 2001 Jun 15;15(9):1125-32.
119. Shulman, NS, Shafer RA, Winters M, Machezano R, Zolopa AR, Liu SH, Hughes M, Katzenstein DA Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. *J Acquir Immune Defic Syndr*. 2001 Aug 1;27(4):377-80.
120. Fletcher CV, Acosta EP, Cheng H, Haubrich R, Fischl M, Raasch R, Mills C, Hu XJ, Katzenstein D, Remmel RP, Gulick RM. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. *AIDS*. 2000 Nov 10;14(16):2495-501.
121. Albrecht MA, Bosch R, Hammer S, Liou S-H, Kessler H, Para M, Eron J, Valdez H, Dehlinger M, Katzenstein DA. Nelfinavir, Efavirenz or both after failure of nucleoside treatment of HIV infection. *New Engl J Med* 2001;345:398-407.
122. Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralknik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McAurthur JC. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. *Neurology* 2001; 57:1313-1356.
123. Lathey JL, Tierney C, Chang S-YP, D'Aquila RT, Bettendorf D, Alexander HC, Santini CD, Hughes AM, Barroga CF, Spector SA, Landes JE, Hammer SM, **Katzenstein DA**. Association of CCR5, CCR2 and Stromal-derived factor 1 genotypes and human immunodeficiency virus disease progression in patients receiving nucleoside therapy. *Journal of Infectious Disease* 2001; 184:1402-11.
124. Mary Kate Morris, **David A. Katzenstein**, Dennis Israelski, Andrew Zolopa, R. Michael Hendry, Carl V. Hanson. Characterization of the HIV-1 Specific Humoral Immune Response During Highly Active Antiretroviral Therapy (HAART). *Journal of Acquired Immune Deficiency Syndromes* 2001;28:405-415
125. Nancy S. Shulman; Michael D. Hughes; Mark A. Winters; Robert W. Shafer; Andrew R. Zolopa; Nicholas S. Hellmann; Michael Bates; Jeannette M. Whitcomb; David A. Katzenstein Subtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients *JAIDS Journal of Acquired Immune Deficiency Syndromes* 31(2): 121-127; Apr 2002
126. David M. Simpson, Anna-Bettina Haidich , Giovanni Schifitto, Constantin T. Yiannoutsos, Anthony P. Geraci, Justin C. McArthur, **David A. Katzenstein** and the ACTG 291 study team. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. *AIDS* 2002;16:407-412.
127. Machezano Rhoderick, MSc, Bassett Mary, MD, MPH, McFarland Willi, MD, DrPH, **Katzenstein David**. Clinical Signs and Symptoms in the assessment of

- immunodeficiency in Men with Subtype C HIV infection in Harare, Zimbabwe. HIV Clinical Trials. Mar-Apr;3(2):148-54. 2002.
128. Polydefkis M, Yiannoutsos CT, Cohen BA, Hollander H, Schifitto G, Clifford DB, Simpson DM, Katzenstein D, Shriver S, Hauer P, Brown A, Haidich AB, Moo L, McArthur JC. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology. 2002 Jan 8;58(1):115-9.
  129. Casseb J, Katzenstein D, Winters M, Brigido LF, Duarte AJ, Hendry RM. Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity. Braz J Med Biol Res. 2002 Mar;35(3):369-75.
  130. Guevara H, Casseb J, Zijenah LS, Mbizvo M, Ocegueda LF 3rd, Hanson CV, Katzenstein DA, Hendry RM. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):435-40.
  131. Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS. 2002 May 24;16(8):1147-54.
  132. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel. JAMA. 2002 Jul 10;288(2):222-35.
  133. Roy M, Gulick, X. Joan Hu, Susan A. Fiscus, Courtney V. Fletcher, Richard Haubrich, Hailong Cheng, Edward Acosta, Stephen W. Lagakos, Ronald Swanstrom, William Freimuth, Sally Snyder, Charlotte Mills, Margaret Fischl, Carla Pettinelli, and David Katzenstein, for the AIDS Clinical Trials Group Protocol 359 Team. Durability of Response to Treatment among Antiretroviral-Experienced Subjects: 48-Week Results from AIDS Clinical Trials Group Protocol 359. The Journal of Infectious Diseases 2002;186:626–33.
  134. Shulman N, Hughes D, Winters M, Shafer M, Zolopa A, Hellmann N, Bates M, Whitcomb JM, Katzenstein, DA. Subtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients. Journal of AIDS 2002; 31:121-128
  135. Lynn S. Zijenah, Wendy Hartogensis, David A. Katzenstein, Ocean Tobaiwa, Junior Mutswangwa, Peter R. Mason, Leslie G. Louie. Association of high HIV-1 RNA levels and homozygosity at HLA class II DRB in adults co-infected with *Mycobacterium Tuberculosis* in Harare, Zimbabwe. Human Immunology 63, 1026–1032 (2002).
  136. Miriam Rabkin, Wafaa El-Sadr, David Katzenstein, Kevin M. De Cock, Joia Mukherjee, Henry Masur, Peter Mugenyi, Paula Munderi and Janet Darbyshire. Antiretroviral therapy in resource-poor settings: Clinical research priorities. Lancet 2002; 360: 1503–05.

137. Rami Kantor, Solomon Mutetwa, Lynn Zijenah, Elizabeth Johnston, Robert Lloyd, Andrea von Lieven, Dennis Israelski, Robert W. Shafer and David A. Katzenstein. HIV-1 subtype C reverse transcriptase and protease genotypes in patients from Zimbabwe failing antiretroviral therapy. *Aids Research And Human Retroviruses* 2002; 18: 1407–1413.
138. Camlin Tierney, Janet L. Lathey, Cindy Christopherson, Daniel M. Bettendorf, Richard T. D'Aquila, Scott M. Hammer, David A. Katzenstein, and the ACTG 175 Virology Team Prognostic Value of Baseline HIV-1 DNA Measurement for HIV Disease Progression in Patients Receiving Nucleoside Therapy. *The Journal of Infectious Diseases* 2003; 187:144–8
139. D. A. Katzenstein , R. J. Bosch, N Hellmann , N Wang , L Bacheler , M. A. Albrecht. Phenotypic Susceptibility And Virologic Outcome In Nucleoside-Experienced Patients Receiving Three Or Four Antiretrovirals. *AIDS* 2003; 17:821-830.
140. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. *AIDS Rev.* 2003 Jan-Mar;5(1):25-35.
141. Elizabeth R. Johnston, Lynn S. Zijenah, Solomon Mutetwa, Rami Kantor, Chonticha Kittinunvorakoon, and David A. Katzenstein High Frequency of Syncytia inducing and CXCR4 tropic viruses among HIV-1 Subtype C infected patients receiving antiretroviral treatment. *J Virol* 2003;77(13):7682-8.
142. Ronald J. Bosch; Gerald F. Downey; David A. Katzenstein; Nicholas Hellmann; Lee Bacheler; Mary A. Albrecht; for the ACTG 364 Study Team. Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. *AIDS* 17 (research notes): 2395-2396; Apr 2003
143. Mark A. Winters, Ronald J. Bosch, Mary A. Albrecht, and David A. Katzenstein for the ACTG 364 Study Team Clinical Impact of the M184V Mutation on Switching to Didanosine or Maintaining Lamivudine Treatment in Nucleoside-Experienced Patients. *J Infect Dis.* 2003 Aug 15;188(4):537-40.
144. Jiang H, Deeks SG, Kuritzkes DR, Lallemand M, Katzenstein D, Albrecht M, DeGruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. *J Infect Dis.* 2003 Oct 1;188(7):1001-8.
145. Avinash K. Shetty, Hoosen M. Coovadia, Mark M. Mirochnick, Yvonne Maldonado, Lynne M. Mofenson, Susan H. Eshleman, Thomas Fleming, Lynda Emel, Kathy George, David A Katzenstein, Jennifer Wells, Anthony Mwatha, Samuel Adeniyi Jones,<sup>j</sup> Salim S Abdool Karim, and Mary T Bassett. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly or weekly in breastfeeding infants from birth to 6 months. *J Acquir Immune Defic Syndr.* 2003 Dec 15;34(5):482-90.
146. Leslie G. Louie, Wendy E. Hartogensis, Rachael P. Jackman, Kathleen A. Schultz, Lynn S. Zijenah, Carina H.-Y. Yiu, Viet D. Nguyen,

Marie Y. Sohsman, David K. Katzenstein, and Peter R. Mason *Mycobacterium tuberculosis*/HIV-1 Coinfection and Disease: Role of Human Leukocyte Antigen Variation. *The Journal of Infectious Diseases* 2004;189:1084-1090

147. Courtney V. Fletcher, Hongyu Jiang, Richard C. Brundage, Edward P. Acosta, Richard Haubrich, David Katzenstein, Roy M. Gulick. Sex Differences in Saquinavir Pharmacology and Virologic Response in AIDS Clinical Trials Group (ACTG) Study 359. *The Journal of Infectious Diseases* 2004;189:1176-1184.
148. Gottlieb D, Shetty AK, RM Mapfungautsi, Bassett MT, Maldonado Y, Katzenstein DA. Infant feeding practices of HIV-infected and uninfected women in Zimbabwe. *AIDS Patient Care and STDs* 2004;18:45-53.
149. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. *J Virol.* 2004 Apr;78(7):3233-43.
150. Clive M Gray, Carolyn Williamson, Adrian Puren, Xiaohu Xia, Ruben Filter, Lynn Zijenah, Huyen Cao, Lynn Morris, Glenda Gray, James McIntyre, David Katzenstein, Newton Kumwenda, Taha Taha, Rosemary Musonda, Efthymia Vardas, Mark Colvin, Salim Abdool Karim, Jorge Flores, Haynes Sheppard Viral Dynamics, Cd4 Counts And Human Leukocyte Antigen Types In Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals From Southern Africa: Significance For Vaccine Trials submitted JV 2003.
151. Lynn S. Zijenah, Ocean Tobaiwa, Simbarashe Rusakaniko, Christine Gwanzura, Arsene Bikoue, Margaret Nhembe, Petronella Matibe, David Katzenstein, and Kusum J Nathoo, George Jannossy. Comparative evaluation of ultrasensitive p24 antigen assay and CD4/CD8 ratio, versus DNA PCR for diagnosis of HIV-1 infection in infants under the age of 2 years, in Harare, Zimbabwe. Submitted to *J Clin Micro* 2003.

## ABSTRACTS

1. Katzenstein DA, Yu G, and Jordan MC. Lethal murine cytomegalovirus (MCMV) infection is mediated by early replication of virus in the spleen. 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Miami, FL, 1982.
2. Katzenstein DA, Yu G, and Jordan MC. Lethal murine cytomegalovirus infection is mediated by early replication in splenic macrophages. Western Society for Clinical Research. Carmel, CA, 1983.
3. Tzamaloukas AH, Ahlin T, Katzenstein DA, and Sterling WA. Association of pulmonary Nocardiosis in renal transplant recipient. Transplantation 33, 5:569, 1983.
4. Burbige EJ, Katzenstein DA, and Chin CK. Effect of cytomegalovirus infection on small intestinal disaccharidases in mice. American Association for the Study of Liver Diseases, Gastroenterology Research Group. Washington, DC, 1983.
5. Katzenstein DA, Crane RT, and Jordan MC. Treatment of lethal murine cytomegalovirus does not prevent latent infection. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 1984.
6. Van Drunen N, Jung BA, Brummett WB, Cameron FD, Edelman C, and Katzenstein DA. A large common source outbreak of Adenovirus type III among hospital personnel. 86th Association for Microbiology. Washington, DC, 1986.
7. De Villiers D, Grace S, Latif A, and Katzenstein DA. Peripheral blood T4 lymphocytes in Zimbabwean patients with HIV infection. Second International Symposium on AIDS and Associated Cancers in Africa. Naples, Italy, 1987.
8. Katzenstein DA, Latif AS, Bassett MT, and Emmanuel JC. Risk of heterosexual transmission of HIV in Zimbabwe. IIIrd International Conference on AIDS. Washington, DC, 1987.
9. Latif AS, Grace S, Carrow EW, Hendry RM, Williams C, Judkins K, Parks E, Katzenstein DA, Emmanuel JC, and Quinnan GV. Differences in HIV-1 antibody responses between U.S. and Zimbabwean individuals. IVth International Conference on AIDS. Stockholm, Sweden, 1988.
10. Latif AS, Marowa E, Grace S, De Villiers D, Mashu A, Katzenstein DA, Bassett M, and Emmanuel J. Persistent generalized lymphadenopathy due to HIV infection in Zimbabwe. IVth International Conference on AIDS. Stockholm, Sweden, 1988.

11. Sawyer LA, Saah A, Katzenstein DA, Vujcic L, Fahey J, Rinaldo C, Phair J, Ginzburg H, Su S, and Quinnan GV. Development of neutralizing antibody to HIV-III<sub>B</sub> is associated with lymphadenopathy and a decrease in CD4 cell number. IVth International Conference on AIDS. Stockholm, Sweden, 1988.
12. Latif AS, Grace S, Katzenstein DA, Vujcic L, Boone E, Hendry RM, and Quinnan GV. Neutralizing antibodies against HIV-1 in Zimbabwean and U.S. patients. IVth International Conference on AIDS. Stockholm, Sweden, 1988.
13. Hendry RM, Sawyer LA, Katzenstein DA, Carrow EW, Williams CC, Judkin KR, Farzadegan H, SuS, Giorgi JV, Gupta Pphair JP, Ginzburg H, and QuinnanGV. Isotype-specific western blots for HIV-1 antibody responses of 20 seroconverters over a 30 month period. Fourth International conference on AIDS, Stockholm, Sweden, 1988.
14. Sawyer LA, Katzenstein DA, Hendry RM, Zeger SL, Boone EJ, Vujcic LK, Williams CC, Quinnan GV, and the Multicenter AIDS Cohort Study. Different roles of antibody-dependent cell-mediated cytotoxicity and neutralizing antibodies in HIV infection. Modern Approaches to New Vaccine Including the Prevention of AIDS. Cold Spring Harbor, NY, 1988.
15. Martin M, Quinnan GV, Carrow E, Hendry RM, Clapham F, Deinhart F, Folks T, Groopman J, Ho D, Langlois A, Nara P, Parks W, Rasheed S, Robert-Guroff M, Vujcic L, and Katzenstein DA. A comparative study of HIV-1 neutralizing antibody assays in 11 laboratories. Modern Approaches to New Vaccine Including the Prevention of AIDS. Cold Spring Harbor, NY, 1988.
16. Sawyer LA, Boone E, Katzenstein DA, Hendry RM, Williams CC, Vujcic LK, Quinnan GV, and the Multicenter AIDS Cohort Study. HIV-1 Antibody-dependent cell-mediated cytotoxicity detectable prior to neutralizing antibody: A study of antibody responses in 39 seroconverters over 2 years. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, CA, 1988.
17. Vujcic LK, Katzenstein DA, Latif AS, Grace S, and Quinnan GV. Neutralizing Antibody (NA) activity of U.S. and Zimbabwean Sera against divergent strains of HIV. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, CA, 1988.
18. Vial P, Katzenstein DA, Grace SA, and Quinnan GV. A rapid method for polymerase chain reaction amplification of HIV DNA in clinical specimens to confirm or detect infection. UCLA Symposium on AIDS and Human Retrovirus Infections Keystone, CO, 1989.
19. Hendry RM, Katzenstein DA, McCutchan JA, Sawyer LA, Vujcic LK, and Quinnan GV. Decreasing antibody responses in association with AIDS. Vth International Conference on AIDS, Montreal, Quebec, 1989.
20. Carrow EW, Katzenstein DA, Sawyer LA, Hendry RM, Boone EJ, and Quinnan GV.

- Functional and envelope binding antibodies to HIV-1 in seropositive subjects from Africa and the Americas. Vth International Conference on AIDS, Montreal, Quebec, 1989.
21. Katzenstein DA, Hendry RM, Nsa W, Ryder C, Brown C, and Quinn, TC. Longitudinal study of HIV antibody responses of infants born to seropositive women in Zaire. Vth International Conference on AIDS, Montreal, Quebec, 1989.
  22. Katzenstein DA, Vujcic LK, Latif A, Galvao B, Halsey N, and Quinnan GV. Neutralizing antibody in seropositive subjects from Africa, South and North America against 4 divergent strains of HIV. Vth International Conference on AIDS, Montreal, Quebec, 1989.
  23. Grace SA, Katzenstein DA, Carrow EW, Vial P, Webb DS, and Quinnan GV. HIV-1 Infection of human monocytes is inhibited by antisera to HIV-1 or by LPS activation of the cells. Vth International Conference on AIDS, Montreal, Quebec, 1989.
  24. Holodniy M, Katzenstein DA, and Sengupta S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, and Merigan TC. Quantification of HIV-1 RNA in serum and correlation with disease status using the polymerase chain reaction. VI International Conference on AIDS, San Francisco, CA, 1990.
  25. Bassett MT, Emmanuel JC, Katzenstein DA, and Latif A. HIV infection in urban men in Zimbabwe. VIth International Conference on AIDS, San Francisco, CA, 1990.
  26. Collier A, Katzenstein D Coombs R, Holodniy M, Mordenti J, Arditti D, Ammann A, Merigan TC, and Corey L. Safety and pharmacokinetics of intravenous recombinant CD4 immunoadhesin (RCD4-IgG). VIth International Conference on AIDS, San Francisco, CA, 1990.
  27. Kundu SK, Katzenstein DA, Smith G, and Merigan TC. HIV specific cellular immune responses in HIV sero-positive and sero-negative subjects. VIth International Conference on AIDS, San Francisco, CA, 1990.
  28. Winters MA, Holodniy M, Katzenstein DA, and Merigan TC. Rapid detection of HIV infectivity and measurement of anti-viral activity using the polymerase chain reaction (PCR) Presented at the UCLA symposia on molecular and cellular biology, Lake Tahoe, CA, 1991.
  29. Merigan TC, Katzenstein DA, and Holodniy M. Correlation between human immunodeficiency virus (HIV) load, stage of disease and dideoxy drug responses using quantitative RNA and DNA polymerase chain reaction (PCR) for viremia. Workshop on Viral Quantitation in HIV infection, Paris, France, 1991.
  30. Moehle-Botani J, Akula S, Holodniy M, Katzenstein DA, and Garcia G. The sulfone syndrome during dapsone treatment for pneumocystis carinii pneumonia (PCP) prophylaxis. VIIth International Conference on AIDS, Florence, Italy, 1991.

31. Blumenfeld W, McCook O, Holodniy M, and Katzenstein DA. Correlation of cytologic diagnosis of pneumocystis carinii with the presence of pneumocystis DNA amplified by the polymerase chain reaction. Presented at the American Cytologic Association Meeting, Los Angeles, CA 1992 and in Acta cytologica, 35:630, 1991.
32. Shafer RW, Katzenstein D, Kozal M, Katzman M, Fiscus S, Meyer W, Gupta P, Coombs R, Rasheed S, Ragni MV, and Merigan TC. Drug susceptibilities of HIV-1 Isolates from asymptomatic HIV-1 infected patients. Submitted to the UCLA symposia on Molecular and Cellular Biology, Keystone, CO, 1992.
33. Holodniy M, Katzenstein DA, Montoya J, Shafer R, Winters M, Ragni, M, and Merigan TC. Decrease in Virus Load Measured by Cell Culture and RNA and DNA PCR in Asymptomatic HIV Infected Patients Treated with Combination Therapy. UCLA symposia on Molecular and Cellular Biology, Keystone, CO, 1992.
34. Katzenstein DA, Valentine F, Kundu S, Hazlett P, Smith G, and Merigan TC. Delayed-Type-Hypersensitivity reactions to intradermal gp160 in HIV infected individuals immunized with gp160. Presented at the VIII International Conference on AIDS, Amsterdam, 1992.
35. Johnson V, Balfour H, Beckett L, Chesboro B, Crumpacker C, Habersett C, Japour A, Katzenstein DA, Kuritzkes D, Mayers D, McIntosh K, Rangan S, Reichman R, Richman D, Scott W, and D'Aquila R. Intralaboratory variability of anti-HIV-1 susceptibility testing. Presented at the VIII International Conference on AIDS, Amsterdam, 1992.
36. Kundu S, Katzenstein DA, Moses LE, and Merigan TC. Enhancement of HIV specific cytotoxic and Helper T cell activities in asymptomatic HIV infected patients given recombinant gp160 vaccine. Presented at the VIII International Conference on AIDS, Amsterdam, 1992.
37. Gwanzura L, Mason P, Winter M, and Katzenstein DA. Microbiologic diagnosis of Pneumocystis Carinii Pneumonia in HIV Positive Patients in Zimbabwe. Presented at the VIII International Conference on AIDS, Amsterdam, 1992.
38. Shafer RW, Kozal MJ, Winters M, Katzenstein DA, Fiscus S, Katzman D, Gupta P, Meyer R, Coombs R, Ragni MV, and Merigan, TC. Combination Therapy with Zidovudine (AZT) and Didanosine (ddI) Selects for Non-Syncytia-Inducing (NSI), AZT Resistant HIV-1 (HIV) Strains Lacking a ddI-Resistance Mutation. Second International Workshop on HIV Drug-Resistance, Noordwijk, The Netherlands, 1993.
39. Kozal M, Shafer R, Winters M, Katzenstein DA, Halpern JH, Aguiniga E, and Merigan TC. SI Phenotype and Codon 215 POL Gene Mutation in PBMC are Initially Independently Associated with CD4 Cell Decline and Increased Proviral Burden in Zidovudine Recipients. Second International Workshop on HIV Drug-Resistance, Noordwijk, The Netherlands, 1993.
40. Katzenstein DA, Winters, M, Israelski D, Bulp J, and Merigan TC. Quantitation of HIV by culture and polymerase chain reaction (PCR) in patients treated with ddI after prolonged

ZDV Therapy. IXth International Conference on AIDS. Berlin, 1993.

41. Machekano R, Bassett M, McFarland W, Ray S, Mbizvo MT, Mvere D, Karangwa M, and Katzenstein DA. Risk Factors for HIV infection among urban, male factory workers in Harare, Zimbabwe. Presented at the VIIIth International Conference on AIDS in Africa. Marakesh, Morocco, 1993.
42. Mvere D, McFarland W, Ray S, Mbizvo MT, Bassett M, Machekano R, Nhau B, Katzenstein D. Blood donor screening in a factory workers in Harare, Zimbabwe. Presented at the VIIIth International Conference on AIDS in Africa. Marakesh, Morocco, 1993.
43. Bassett M, Mbizvo MT, Ray S, McFarland W, Machekano R, Mvere D, Maposhere C, and Katzenstein DA. Separation from wife, high risk behavior and HIV infection among male factory workers in Harare, Zimbabwe. Presented at the VIIIth International Conference on AIDS in Africa. Marakesh, Morocco, 1993.
44. Mbizvo MT, Ray S, Bassett M, McFarland W, Machekano R, Mvere D, Mashigaidze R, and Katzenstein DA. Condom use among urban, male factory workers in Harare, Zimbabwe. Presented at the VIIIth International Conference on AIDS in Africa. Marakesh, Morocco, 1993.
45. Ray S, Bassett M, Mbizvo MT, McFarland W, Machekano R, Mvere D, Mzezewa V, and Katzenstein DA. Workplace AIDS education in Harare, Zimbabwe. Presented at the VIIIth International Conference on AIDS in Africa. Marakesh, Morocco, December, 1993.
46. Kozal, MJ, Kroodsma K, Winters M, Shafer R, Efron B, Katzenstein DA, and Merigan T. DDI and ZDV resistance mutations in 64 patients switched from ZDV to DDI: Relationship to CD4 cell decline and virus burden and disease progression. Third International Workshop on HIV Drug Resistance, Kauai, HI, 1994.
47. Shafer R, Iversen AKN, Winters MA, Aquiniga E, Katzenstein DA, and Merigan TC. Complexity of HIV reverse transcriptase changes in patients receiving the combination of AZT+DDI for 2 years: associations between drug resistance, virus load, and CD4 Counts. Third International Workshop on HIV Drug Resistance, Kauai, HI, 1994.
48. Yen-Lieberman B, Brambilla D, Jackson B, Palumbo P, Herman S, Cronin M, Todd HJ, Lin M, Vahey M, Katzenstein DA, Bremer J, Coombs R, and Reichelderfer P. Establishment of a quality assurance program (QAP) for quantitation of HIV-1 plasma RNA by the AIDS Clinical Trials Group (ACTG). Presented at the 19th AIDS Clinical Trials Group Meeting, Washington, DC, 1995.
49. Mashayamombe S, Machekano R, Maposhere C, Mosher S, McFarland W, Ray S, van de Wijgert J, and Katzenstein D. HIV serologic discordance in couples recruited for HIV testing and counseling in Harare Zimbabwe. Presented at the VIIIth National Collaborative Vaccine Development Group, Washington DC, 1996.

50. Machezano R, McFarland W, Mashayamombe S, Ray S, van de Wijgert J, Maposhere C, Mbizvo M, Bassett M, and Katzenstein DA. HIV testing and counseling and change risk behavior and HIV seroconversion in male factory workers in Harare, Zimbabwe. Presented at the VIIIth National Collaborative Vaccine Development Group, Washington DC, 1996.
51. M. ALBRECHT\*, D. KATZENSTEIN, R. BOSCH, S. LIOU, S. HAMMER for the ACTG 364 Study Team, NIAID Sponsored AIDS Clinical Trials Group, Bethesda, MD. ACTG 364: Virologic Efficacy of Nelfinavir (NFV) and/or Efavirenz (EFZ) in Combination with New Nucleoside Analogs in Nucleoside Experienced Subjects (subj). (489) Presented at the 6<sup>th</sup> annual Conference on Retroviruses and Opportunistic Infections. Chicago, 52.
51. Katzenstein DA, Hammer S, Hughes M, Gundacker H, Jackson B, Winters M, Merigan T, Hirsch M, and the ACTG 175 Virology Study Team. Combination and Monotherapy with ZDV, ddI, and ddC. Suppression of Plasma HIV RNA by Reverse Transcriptase Inhibitors (RTI) Prevents AIDS and Death in ACTG 175, Presented at the Xth International Conference on AIDS, Vancouver, BC, July 6-10, 1996.
52. David Rey, Michael Hughes, Ju-Tsung Pi, Mark Winter, Thomas C Merigan, and David A Katzenstein for the ACTG 175 Virology Team. Human immunodeficiency virus type 1 reverse transcriptase codon 215 mutation in plasma RNA. Immunologic and virologic responses to Zidovudine in ACTG 175. Presented at the 4<sup>th</sup> National Retrovirus Conference, Washington, D.C. Jan 22-26, 1997.
53. Lynn Zijenah, Marshall Majoma, Simon Madzime, Yvonne Maldonado, Kussam Nathoo, Mike Mbizvo, and David Katzenstein. Vertical Transmission of Human Immunodeficiency Virus and Infant Mortality in Zimbabwe. Presented at the 4<sup>th</sup> National Retrovirus Conference, Washington, D.C. Jan 22-26, 1997.
54. Mbizvo M, DA Katzenstein, T Gittens, L Zejenah, K Nathoo, M Majoma, Y Maldonado. Maternal HIV serum RNA levels and infant mortality and vertical transmission of subtype-C HIV in Zimbabwe. Presented at The Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Sept 3-6, 1997, Washington, D.C.
55. Zolopa AR, Shafer R, Warford A, Montoya JG, Katzenstein D, Merigan TC. HIV Genotypic Progressions of Antiviral Response to Saquinavir/6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL 1999 (Abstract 93).
56. Tien P, Contag C, Katzenstein D. Maternal subtype C HIV-1 RNA quasispecies diversity and risk of mother to child transmission in Zimbabwe. Presented at the Infectious Disease Society of America, Denver Co, NOV 12-15, 1998.
57. D Katzenstein, R Bosch, R Shafer, M Albrecht, M Winters, S Hammer. Reverse

Transcriptase Genotype After Multiple, Sequential Nucleoside Analog Drugs and the Response to HAART in ACTG 364 (Abstract 138). Presented at the 6<sup>th</sup> National Retrovirus Conference, Chicago Feb 1-3, 1999.

58. D Katzenstein, H Guevara, M Hendry, T Gittens, L Zijena, M Mbizvo. Maternal HIV-1 RNA and V3 Antibodies Predict Risks For Vertical Transmission and Mortality In Subtype C Virus Infection. (Abstract 235). Presented at the 6<sup>th</sup> National Retrovirus Conference, Chicago Feb 1-3, 1999.
59. H Guevara, O Tobaiwa, K Mohhamed, P Mason, M Hendry, D Katzenstein HIV RNA in Maternal and Cord Plasma. Evidence for in utero prenatal transmission of Subtype C HIV-1 infection in Zimbabwe. Presented at the 6<sup>th</sup> National Retrovirus Conference, Chicago Feb 1-3, 1999.
60. Morris MK, Hanson C, Hendry M, Israelski D, Zolopa AR, Tenney R, Guevara H, Tan G, Katzenstein D. Antibody Titers Prior to HAART Predict Treatment Outcome. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL 1999 (Abstract 353)
61. R Machekano, M Bassett, W McFarland and D Katzenstein. Clinical Signs and Symptoms of Subtype C HIV infection and predictors of mortality among heterosexual men in Harare, Zimbabwe. 13<sup>th</sup> International AIDS Conference, Durban, South Africa.
62. L Gwanzura, R Machekano, M Bassett, W McFarland and D Katzenstein HIV1 / HSV-2 co-infection and sero-concordance among heterosexual couples in Harare, Zimbabwe 13<sup>th</sup> International AIDS Conference, Durban, South Africa.
63. Shulman N, Zolopa A, Murlidharan U, Israelski D, Brosgart C, Miller M, Van Doren S, Shafer R, Katzenstein D. Salvage therapy with an efavirenz (EFV) and adefovir (ADV)-based regimen in antiretroviral experienced patients. Abstract 13 in 2<sup>nd</sup> International Workshop on Salvage Therapy for HIV Infection, May 19-21, 1999, Toronto. (Oral Presentation). Received Young Investigator Scholarship for travel and meeting fees.
64. Shulman N, Zolopa A, Murlidharan U, Israelski D, Brosgart C, Miller M, Shafer R, Katzenstein D. Responses to salvage therapy with an efavirenz and adefovir-based regimen in antiretroviral experienced patients: a genotypic study. Abstract 101 in 3<sup>rd</sup> International Workshop on Drug Resistance and Treatment Strategies, June 23-26, 1999, San Diego.
65. Shulman N, Zolopa A, Murlidharan U, Israelski D, Brosgart C, Miller M, Shafer R, Katzenstein D. Efavirenz and adefovir-based salvage in antiretroviral experienced HIV+ patients. Abstract 2201 in 39<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep 26-29, 1999, San Francisco.
66. Shulman N, Zolopa A, King H, Whitcomb J, Passaro D, Israelski D, Shafer R, Katzenstein D, Petropoulos C, Hellmann N. NNRTI hyper-susceptibility in a well-characterized cohort of treatment – experienced patients receiving efavirenz and adefovir salvage regimens. Abstract 99 in 4<sup>th</sup> International Workshop on Drug Resistance and Treatment Strategies, June 12-16, 2000, Sitges, Spain.
67. Louie L, Graves A, Wells J, Hartogensis W, Jackman R, Zijenah L, Yiu C, Nguyen V, Schultz K, Katzenstein D, Mason P. Genetic Influence on risk of active tuberculosis (TB) in Zimbabwe. (poster presentation) 33<sup>rd</sup> Annual Meeting of the Society for Epidemiologic Research, Seattle, WA, June, 2000.
68. Louie L, Hartogensis W, Jackman R, Zijenah L, Yiu C, Nguyen V, Schultz K, Katzenstein D, Mason P. HLA and risk of tuberculosis in Zimbabwe. (oral presentation) 26<sup>th</sup> Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Orlando, FL, Oct. 2000.
69. J. LATHEY\*, C. TIERNEY, S. CHANG, R. D'AQUILA, S. HAMMER, D. KATZENSTEIN, and the ACTG 175 Genotype Team. NIAID, Bethesda, MD Homozygous Mutations in 3'A SDF-1 Are Associated with More Rapid Disease Progression (Abstract 853). The 7th National Conference on Retroviruses and Opportunistic Infections, San Francisco, CA January 30-February 4, 2000

70. Shulman N, Shafer R, Winters M, Machezano R, Liou S, Hughes S, Zolopa A, Katzenstein D. Genotypic predictors of virologic response to stavudine after zidovudine monotherapy (ACTG 302). Abstract 437 at 8<sup>th</sup> International Conference on Retroviruses and Opportunistic Infections, 2000, Feb 4-8, Chicago.
71. Hugo Guevara, Elizabeth Johnston, Phyllis Tien, Lynn Zijenah, Chris Contag, Michael Hendry and David Katzenstein. Maternal Viral Diversity, V3 Antibodies and the Vertical Transmission of HIV-1 Subtype C. Presented at the 1<sup>st</sup> IAS Conference on HIV Pathogenesis and Treatment. July 8-11, 2001, Buenos Aires, Argentina.
72. Zijenah LS, Hartogensis W, Louie L, Tobaiwa O, Mutswangwa J, Herman S, Mason P, Katzenstein D. *Mycobacterium tuberculosis* infection, skin test reactivity and subtype C HIV-1 RNA in Zimbabwe. (poster presentation) 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 2001.
73. Katzenstein D, Shulman N, Bosch R, Liou S, Whitcomb J, Hellman N, Albrecht M. Genetic correlates of phenotypic hypersusceptibility to efavirenz in highly nucleoside experienced subjects in ACTG 364. In: *1st IAS Conference on Pathogenesis and Treatment*. Buenos Aires, Argentina, 4-8 July 2001 [Abstract no. 594].
74. Hartogensis W, Jackman R, Schultz K, Yiu C, Nguyen V, Zijenah L, Katzenstein D, Mason P, Louie L. HLA and TB disease progression in Zimbabwe. (poster presentation) 36<sup>th</sup> Tuberculosis and Leprosy Research Conference. New Orleans, July 2001.
75. Hartogensis W, Jackman R, Schultz K, Yiu C, Nguyen V, Zijenah L, Katzenstein D, Mason P, Louie L. HLA and tuberculosis (TB) disease progression in Zimbabwe. (poster presentation, abstract #81) 27<sup>th</sup> Annual Meeting of the American Society for Histocompatibility and Immunogenetics, San Francisco, October, 2001.
76. C. V. Fletcher, H. Cheng, S. A. Fiscus, R. Swanstrom, N. S. Hellmann, R. Haubrich, D. Katzenstein, and R. Gulick for the ACTG 359 Team The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy (Abstract 129). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb24-28, 2002.
77. E. Johnston, S. Mutetwa, L. Zijenah, A. von Lieven, D. Israelski, C. Kittinunvorakoon, R. Kantor, and D. Katzenstein. Presence of CXCR4-Tropic Viruses among Subtype C HIV-Infected Individuals (Abstract M-137). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb24-28, 2002.
78. M. A. Albrecht, R. J. Bosch, S. H. Liou, and D. Katzenstein. Efficacy of Nelfinavir (NFV) and/or Efavirenz (EFV) in Combination with New NRTIs in Nucleoside Experienced Subjects: Week-144 Results. (Abstract 566 -T). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb24-28, 2002.
79. R. Swanstrom, D. Katzenstein, N. S. Hellmann, S. A. Fiscus, L. Petch, H. Cheng, R. Haubrich, and R. Gulick Selection for Delavirdine (DLV) Resistance is not Associated with Loss of Nucleoside Analogue (NRTI) Resistance Mutations in Subjects with Non-Nucleoside Analogue (NNRTI) Hypersusceptibility -- Results from ACTG 359 (Abstract 567 -T). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb24-28, 2002.
80. D. Katzenstein, R. J. Bosch, N. Wang, N. S. Hellmann, L. Bacheler, and M. Albrecht for the ACTG 364 Study Team Baseline Phenotypic Susceptibility and Virologic Failure over 144 Weeks among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364. (Abstract 591 -T). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb24-28, 2002.
81. R. C. Brundage, E. Acosta, R. Haubrich, D. Katzenstein, R. Gulick, and C. V. Fletcher. Quantitation of Sex Differences and Drug Interactions: Pharmacologic Studies of Saquinavir (SQV) in ACTG 359.

- (Abstract 779-W). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb24-28, 2002.
82. R. Kantor, R. Lloyd, R. Shafer, E. Johnston, L. Guay, J. B. Jackson, S. H. Eshleman, D. Katzenstein. Comparison of Mother-to-Child Transmission (MTCT) and Genotypic Resistance in HIV-1 Subtypes A, C, and D after Single Dose Nevirapine (sd-NVP) in Africa(abstract 801-W). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb24-28, 2002.
  83. MA Winters, RJ Bosch, MA Albrecht and DA Katzenstein for the ACTG 364 Study Team. Clinical Impact of the M184V Mutation on Switching to Didanosine or Maintaining Lamivudine Treatment. Presented at the 6th International HIV Resistance meeting, Seville July 2-5, 2002.
  84. D Katzenstein, Gerald Downey, Ronald Bosch, Nick Hellmann, Mark Becker, and Mary Albrecht for the ACTG 364 Virology team. Evolution of Protease Phenotype and Genotype Changes at Initial and Continued Virologic Failure among Nucleoside-Experienced Subjects Receiving Nelfinavir (NFV) in ACTG 364. Presented at the 6th International HIV Resistance meeting, Seville July 2-5, 2002.
  85. R Kantor, D Katzenstein, M Gonzales, S Sirivichayakul, P Cane, C Pillay, J Snoeck, Z Grossman, A-M Vandamme, L Morris, D Pillay, P Phanuphak, JM Schapiro and RW Shafer Influence of subtype and treatment on genetic profiles of HIV-1 RT and protease: Do they act independently in predicting position-specific mutation probabilities in non-subtype B sequences?. Presented at the 6th International HIV Resistance meeting, Seville July 2-5, 2002.
  86. S. Moyo, M. Mhazo, P. Mateta, A. von Lieven, A.K. Shetty, Y. Maldonado, C. Maponga, D. Katzenstein, M.T. Bassett [ThPeF8027] Feasibility of HIV/AIDS counseling for pregnant women using community volunteers: Experience from Zimbabwe.abstract [ThPeF8027] Presented at the XIVth International AIDS Conference, Barcelona, Spain July 7-12, 2002.
  87. H.P. Binswanger, J. Aguais , T.M. Aguais , L. Francis ,Y.M. Gouna , D. Israelski , D. Katzenstein , M. Katana , A. Marty-Lavauzelle , M. Lavandera-Diaz , R. Machezano , M.J. Mbuzenakambwe , S. Mutetwa , P. Nyamba, F. Ndayishimiye<sup>1</sup>, A. Sall , I. Tiendrebeogo Potential and performance of the association-based treatment model in poor countries [WePeF6761] Presented at the XIVth International AIDS Conference, Barcelona, Spain July 7-12, 2002.
  88. L.S. Zijenah, W.E. Hartogensis , D.A. Katzenstein , O. Tobaiwa , J. Mutswangwa , P.R. Mason , L.G. Louie Association of high HIV-1 RNA levels and homozygosity at HLA class II DRB in adults coinfectd with Mycobacterium Tuberculosis in Harare, Zimbabwe [WePeA5763] Presented at the XIVth International AIDS Conference, Barcelona, Spain July 7-12, 2002.
  89. R.N. Machezano, M.T. Bassett, W. McFarland, D.A. Katzenstein Self-reported clinical signs and symptoms in the prognostic assessment of severe immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe [TuPeC4895] ] Presented at the XIVth International AIDS Conference, Barcelona, Spain July 7-12, 2002.
  90. R. Kantor, D. Katzenstein , P.A. Cane , L. Morris , J. Snoeck , A.M. Vandamme , C. Pillay , D. Pillay , J.M. Schapiro , R.W. Shafer Classical subtype B resistance mutations and novel candidate non-subtype B resistance mutations in treated persons with non-B HIV-1 isolates. [TuPeB4614]. Presented at the XIVth International AIDS Conference, Barcelona, Spain July 7-12, 2002.

91. S. Moyo, A.K. Shetty , J. Wells Y. Maldonado , M. Mhazo , D. Katzenstein , M.T. Bassett Experience and concerns of HIV infected women enrolled in MTCT program in Zimbabwe. [TuPeE5198] Presented at the XIVth International AIDS Conference, Barcelona, Spain July 7-12, 2002.
92. P. Mateta, L. Stranix , S. Moyo N. Nyoni , M. Mhazo , A. von Lieven , L. Langhaug , Y. Maldonado , D. Katzenstein , D. Hill , N. Gonah , A.K. Shetty , M.T. Bassett Feasibility of preventing mother-to-child transmission of HIV in Zimbabwe[B10499]. ] Presented at the XIVth International AIDS Conference, Barcelona, Spain July 7-12, 2002.
93. Louie LG, Hartogensis WE, Jackman RP, Schultz KA, Zijenah LS, Yiu CH-Y, Nguyen VD, Sohsman MY, Katzenstein D, Mason PR. Human leukocyte antigen (HLA) Variation and risk of tuberculosis (TB) in the presence of HIV-1 infection in Zimbabwe. (poster presentation) 13<sup>th</sup> International Histocompatibility Conference, Seattle, WA, May 2002.
94. R Kantor, D Katzenstein, M Gonzales, AP Carvalh, B Wynhoven, M Soares, P Cane, J Snoeck, S Sirivichayaku, K Ariyoshi, A Holguin, C Pillay, P Weidle, Z Grossman, R Rodrigues, MB Bouzas, P Cahn, LF Brigido, L Morris, V Soriano, W Sugiura, P Phanuphak, AM Vandamme, D Pillay, A Tanuri, R Harrigan, R Camacho, JM Schapiro and RW Shafer, Genotypic analyses of RT and protease sequences from persons infected with non- subtype B HIV-1. 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA Feb 10-14, 2003.
95. E. Lee, R. Kantor, E. Johnston and D. Katzenstein HPTN023 Study Team Breast milk shedding of subtype C HIV-1 among women receiving single dose NVP. 10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Boston, MA Feb 10-14, 2003.
96. R Kantor, E Lee, E Johnston, P Mateta, L Zijenah, Y Maldonado and D Katzenstein for the HPTN 023 Study Team. Rapid Flux in NNRTI Resistance Mutations Among Subtype C HIV-1 Infected Women after Single Dose Nevirapine. Presented at the XIIth annual HIV Drug Resistance Workshop. Cabo San Lucas, Mexico. June 10-14,2003.
- 97.
98. R Kantor, AP Carvalho, B Wynhoven, MA Soares, P Cane, J Clarke, J Snoeck, C Pillay, S Sirivichayakul, K Ariyoshi<sup>0</sup>, A Holguin, H Rudich, R Rodrigues, MB Bouzas, P Cahn, LF Brigido, Z Grossman, V Soriano, W Sugiuro, P Phanuphak, L Morris, A-M Vandamme, J Weber, D Pillay, A Tanuri, PR Harrigan, R Camacho, J Schapiro, RW Shafer, and D Katzenstein Nucleic Acid Differences between *HIV-1* non-B and B Reverse Transcriptase and Protease Sequences at Drug Resistance Positions. Presented at the XIIth annual HIV Drug Resistance Workshop. Cabo San Lucas, Mexico. June 10-14,2003.
99. Levy, V<sup>1 2</sup>Chen S<sup>3</sup> ; Page-Shafer K<sup>4</sup>; Prentiss D<sup>2</sup> ;Katzenstein DA<sup>1 2</sup> and Israelski DM<sup>1 2</sup> Mapping Local Geography of HIV Late Presenters in a Northern California County AIDS Program. Presented at the Prevention conference, Atlanta, Ga 2003.
100. Eric J. Arts, Awet Abraha, Erica Fraundorf, Andre Marozsan, Betsy Johnston, David Katzenstein. Rare SI, CXCR4-tropic HIV-1 isolates of subtype C are less fit than any other group M HIV-1 isolate. Second IAS Pathogenesis and Treatment Conference, Paris 2003.
101. C.V. Fletcher, H. Jiang, R.C. Brundage, E.P. Acosta, R. Haubrich, D. Katzenstein, R. Gulick. Sex Differences In Virologic Response And Saquinavir (Sqv) Pharmacology In

Actg 359. Second IAS Pathogenesis and Treatment Conference, Paris 2003.

102. D. Bhattacharya, G. Kadzirange, LS. Zijenah, E Matsikire, S Moyo, T Kufa, O Tobaiwa, M Chirenge, C Maonga, R Machekano, D Katzenstein. Clinical monitoring of cotrimoxazole, duovir and nevimune (generic HAART) among men and women with AIDS in Zimbabwe abstract \_\_\_\_, Presented at the 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA Feb 8-11, 2004.
103. E Johnston, M Ketunuti, R Kantor, D Bhattacharaya, L Zijenah, and D Katzenstein. Persistence of X4-tropic Virus Despite Antiretroviral Treatment in Subtype C HIV. abstract \_\_\_\_, Presented at the 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA Feb 8-11, 2004.
104. N Shulman, RJ Bosch, J Mellors, M Albrecht, and D Katzenstein for the DACS 217 team. The Genotypic Correlates of NNRTI Hypersusceptibility: results of an updated DACS 217 analysis. abstract \_\_\_\_, Presented at the 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA Feb 8-11, 2004.
105. R Kantor, RW Shafer, B Efron, AP Carvalho, B Wynhoven, MA Soares, P Cane, J Clarke, J Snoeck, S Sirivichayakul, K Ariyoshi, A Holguin, C Pillay, H Rudich, R Rodrigues, MB Bouzas, P Cahn, LF Brigido, Z Grossman, L Morris, V Soriano, W Sugiura, P Phanuphak, AM Vandamme, J Weber, D Pillay, A Tanuri, PR Harrigan, R Camacho, JM Schapiro and D Katzenstein. HIV-1 Subtype-Related Differences in Genotypic Evolution: Analysis of Subtypes B and C Reverse Transcriptase (RT) and Protease Sequences. abstract \_\_\_\_, Presented at the 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA Feb 8-11, 2004.
106. Esther Lee, Elizabeth Johnston, Patrick Mateta, Lynn Zijenah, Yvonne Maldonado and David Katzenstein for the HPTN 023 Study Team. Maternal Single Dose Nevirapine May Limit Breast-milk HIV-1 Transmission and Effects of Mastitis up to 2 weeks Post Delivery. abstract \_\_\_\_, Presented at the 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA Feb 8-11, 2004.
107. K Henry, P Tebas, DCherng, MBlanchard Vargas, JSchmitz, DKatzenstein, NJahed, WPowderly and others for the A5102 team. Interleukin-2 (IL-2) Prior to Stopping Effective Antiretroviral Therapy (ART) Prolongs Time Off Potent ART: Initial Results of a Pilot Study Utilizing CD4+ T-cell < 350 Cells/mm<sup>3</sup> as the Threshold for Restarting ART (ACTG A5102). abstract \_\_\_\_, Presented at the 11<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, San Francisco, CA Feb 8-11, 2004.
108. M Ketunuti, R Kantor, M Papathanasopoulos, L Morris, D Katzenstein. Nef Diversity in Sequences from Subtype C HIV-1 Infected Children associated with Disease Progression abstract \_\_\_\_ presented at Keystone, 2004.



## BOOKS AND MONOGRAPHS

1. Katzenstein DA. Chlamydial Infections, Continuing Education, pp 34-45, August, 1982.
2. Katzenstein DA. Amebic Liver Abscess. In International Textbook of Infectious Disease and Microbiology (Ed. by A. Braude, Saunders, Philadelphia), pp 924-928, 1984.
3. Katzenstein DA. The sexual transmission of viral infections. Continuing Education for the Family Physician, 19:18-28, 1984.
4. Reed SL, and Katzenstein DA. Drug treatment of amebiasis. In Antimicrobial Therapy (Ed by P. Peterson, Elsevier, Amsterdam), pp 275-281, 1985.
5. Katzenstein DA. Herpes Virus Infections. In Textbook of Internal Medicine (Ed. by J. Stein, Saunders, Philadelphia), pp 605-1614, 1990.
6. Katzenstein DA, Sawyer LA, and Quinnan GV. Human Immunodeficiency Virus. In Viral Vaccines (Ed. by S. Plotkin, Saunders, Philadelphia), pp. 558-67, 1988.
7. Katzenstein DA, Sawyer LA, and Quinnan GV. Editorial review: Issues in the evaluation of AIDS vaccines. AIDS, 2:151-155, 1988.
8. Sawyer LA, Katzenstein DA, and Quinnan GV. Regulatory Concerns Regarding AIDS Vaccine Development. AIDS and Public Policy, 3:36-45, 1988.
9. Katzenstein DA. The Epidemiology of human immunodeficiency type 2 (HIV-2). Update, testing in the blood bank. (Ed. by Thomas C. Quinn) 4:3-4, 1990.
10. Katzenstein DA and Holodniy M. Quantitative virologic measures of antiretroviral therapy. In Aids Clinical Review. (Ed. by Volberding and Jacobson). Marcel Dekker Inc., NY, NY, pp 41-67, 1992.
11. Katzenstein DA. Virologic Measurements in the Assessment and Treatment of HIV Infection. Part II: Management Issues in HIV/AIDS. (Ed. by Lawrence Corey) American Journal of Medicine educational supplement, November 1994.
12. David A Katzenstein. Adherence as a particular issue with protease inhibitors. Journ Assoc Nurses in AIDS 8 Supplement, 1997.
13. Katzenstein, DA, Lyons C, Ungvarski P, Wolfe GS, Williams A. HIV therapeutics: confronting adherence. Journ Assoc Nurses in AIDS 8 Supplement, 1997.
14. Louise Lawson, David Katzenstein, Sten Vermund. "Emerging Biomedical Interventions" p 43-66 in Preventing HIV in Developing Countries (Edited by L Gibney, RJ Clemente and S Vermund) Kluwer Academic / Plenum Publishers, New York, 1999.
15. David A Katzenstein, The regulation of HIV therapy to prevent resistance development. Current Opinion in Anti-infective Investigational Drugs 1999; 1:150-154.

16. [Shulman NS](#), Katzenstein D. Second-line therapy: Strategies after PI or NNRTI failure. *HIV Advances in Research and Therapy*, Vol 9(1): 16-22, 1999.
17. [Mason PR](#), [Katzenstein DA](#). HIV Treatment in Developing Countries. *Curr Infect Dis Rep*. 2000 Aug;2(4):365-370.
18. DA Katzenstein. Vertical transmission of HIV in Africa: diagnostic testing and new interventions. *HIV Clin Trials*. 2000 Nov-Dec;1(3):51-7.
19. Practical Guidelines in Antiviral Therapy. CA Boucher, GJ Galasso, Contributing editors DA Katzenstein and David A Cooper. Elsevier, 2002.
20. Lynn Zijenah and David Katzenstein. Immunopathogenesis of AIDS (pages 34-52). *AIDS in Africa* (Essex, Kanki and Mboup) Elsevier, 2001.
21. David Katzenstein. Treatment During Pregnancy. *Antimicrobial Therapy and Vaccines I*. second edition 2002; 1278-82. editors Victor Yu, Rainer Weber, and Didier Raoult. AppleTree Productions LLC, NY.
22. David Katzenstein, Maria Laga, Jean-Paul Moatti (Editors). The UNAIDS Drug Access Initiatives in Cote d'Ivoire. Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. *AIDS* 2003; 17:S1-S113. (Supplement to AIDS).